SeekingAlpha · Aug 11, 2026
Regenxbio's Multi-Catalyst Setup Is Hard To Ignore (Rating Upgrade)
Regenxbio surged on milestone revenue and EPS beat, with a $313M cash runway to 2027. Click here to read my most recent analysis.
RG
NASDAQ · RGNX
REGENXBIO Inc.
Healthcare · Biotechnology
$10.91
Down-$0.25 (-2.29%)
Updated Aug 14, 2026, 1:51 AM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 650.96M
- P/E ratio
- -3.74
- Dividend yield
- 0.00%
- 52-week range
- $5.46 – $15.88
- Volume
- 877.34K
- Avg. volume
- 586.76K
Price performance
RGNX price history
1M range · 20 trading sessions · Daily adjusted prices
RGNX closed at $10.91 after 20 trading sessions, down 2.59% for the selected period.
- Last close
- $10.91
- Period change
- -2.59%
- Period low
- $9.60
- Period high
- $11.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $10.77 | $11.21 | $10.675 | $10.91 | 877.34K |
| Aug 11, 2026 | $10.56 | $10.79 | $10.15 | $10.65 | 881.2K |
| Aug 10, 2026 | $10.52 | $10.87 | $10.27 | $10.42 | 988.83K |
| Aug 7, 2026 | $11.05 | $11.39 | $10.31 | $10.72 | 1.39M |
| Aug 6, 2026 | $11.28 | $11.50 | $10.85 | $11.28 | 1.77M |
| Aug 5, 2026 | $10.32 | $10.79 | $10.20 | $10.50 | 1.52M |
| Aug 4, 2026 | $10.13 | $10.43 | $9.871 | $10.30 | 968.72K |
| Aug 3, 2026 | $9.75 | $10.01 | $9.31 | $9.96 | 812.9K |
| Jul 31, 2026 | $10.25 | $10.38 | $9.635 | $9.69 | 1.16M |
| Jul 30, 2026 | $9.75 | $10.14 | $9.53 | $10.12 | 1.22M |
| Jul 29, 2026 | $9.65 | $9.8999 | $9.46 | $9.62 | 1.09M |
| Jul 28, 2026 | $9.59 | $9.77 | $9.175 | $9.60 | 1.39M |
| Jul 27, 2026 | $10.05 | $10.51 | $9.655 | $9.71 | 1.25M |
| Jul 24, 2026 | $10.24 | $10.3359 | $9.57 | $9.73 | 974.33K |
| Jul 23, 2026 | $9.94 | $10.32 | $9.675 | $10.25 | 1.36M |
| Jul 22, 2026 | $10.08 | $10.50 | $10.0109 | $10.20 | 1.15M |
| Jul 21, 2026 | $10.19 | $10.49 | $9.9209 | $10.34 | 1.98M |
| Jul 20, 2026 | $10.01 | $10.78 | $10.01 | $10.32 | 2.28M |
| Jul 17, 2026 | $8.99 | $10.24 | $8.42 | $9.89 | 7.52M |
| Jul 16, 2026 | $12.15 | $12.15 | $11.015 | $11.20 | 2.01M |
Latest RGNX news
The latest Smart Investors Daily articles mentioning RGNX.
Stock researchCompany · Overview
RGNX research
Overview
Company profile and research snapshot.
Company profile
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $30.14
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Barclays | Equal-Weight | — |
| Jun 24, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 22, 2026 | Leerink Partners | Outperform | — |
| Jun 22, 2026 | Baird | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgraded PTGX, LECO, and JHX. See analyst ratings and price targets for these stocks.
Benzinga · Aug 10, 2026
HC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $23
HC Wainwright & Co. analyst Yi Chen maintains Regenxbio (NASDAQ:RGNX) with a Buy and lowers the price target from $26 to $23.
Benzinga · Aug 7, 2026
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
Wall Street analysts changed outlook on top names. For rating changes, check our analyst ratings page. See analysts' views on ADIG, TSEM and more
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
